Eli Lilly (LLY)
(Delayed Data from NYSE)
$887.16 USD
+1.61 (0.18%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $884.12 -3.04 (-0.34%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$887.16 USD
+1.61 (0.18%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $884.12 -3.04 (-0.34%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth A Momentum F VGM
Zacks News
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
Eli Lilly Soars on Blockbuster Q2 Earnings: ETFs to Tap
by Sweta Killa
Eli Lilly (LLY) experienced its most significant surge in stock prices in over two decades following the release of an impressive second-quarter 2023 earnings report and an optimistic outlook. ETFs having the largest exposure to the drug maker could be compelling picks to tap the strong growth.
Company News for Aug 9, 2023
by Zacks Equity Research
Companies in The News Are:LLY,UAA,ATKR,HZNP
Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss
by Zacks Equity Research
Nektar (NKTR) incurs a narrower-than-expected second-quarter loss but misses on revenues.
Zacks Investment Ideas feature highlights: DraftKings, Eli Lilly and Emerson Electric
by Zacks Equity Research
DraftKings, Eli Lilly and Emerson Electric have been highlighted in this Investment Ideas article.
3 Stocks to Buy Following Beat-and-Raise Quarters
by Derek Lewis
All three of these stocks saw buying pressure following better-than-expected results. Should investors ride the earnings momentum?
Eli Lilly (LLY) Q2 Earnings Beat, Mounjaro Powers Sales Growth
by Zacks Equity Research
Eli Lilly (LLY) beats second-quarter estimates for earnings and sales. It raises its financial guidance for 2023.
U.S. Trade Deficit Decreased in June
by Zacks Equity Research
U.S. Trade Deficit Decreased in June
Compared to Estimates, Lilly (LLY) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Pre-Markets Give Back Some Gains; UPS, LLY, QSR Report
by Mark Vickery
Off mid-July highs for the year, we've been a bit more bipolar -- and decidedly to the downside since the start of August.
Eli Lilly (LLY) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of 6.57% and 10.05%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Indices Fight Back; PLTR Meets, SWKS and PARA Beat
by Mark Vickery
The Dow climbed back +408 points on the day, +1.16%, while the Nasdaq gained +84 points, +0.61%.
Drug, Biotech Stocks' Q2 Earnings on Aug 8: LLY, LGND & More
by Kinjel Shah
Let us look at five drug/biotech companies, LLY, LGND, NVAX, EBS and BLUE, which are gearing up for their earnings release.
Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several drugs and may have boosted Eli Lilly's (LLY) second-quarter sales.
Incyte (INCY) Beats on Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Incyte (INCY) reports impressive Q2 earnings on strong uptake in Jakafi and Opzelura sales. The company raises the bottom end of full-year guidance, setting a new range of $2.58-$2.63 billion.
Merck (MRK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 5.07% and 4.50%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Results, MRK, MRNA Cancer Jab in Phase III
by Kinjel Shah
AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $459.32, moving -0.59% from the previous trading session.
Pharma Stock Roundup: JNJ, NVS Upbeat Q2 Results, FDA Nod to SNY & AZN RSV Antibody
by Kinjel Shah
FDA approves AstraZeneca (AZN) and Sanofi's (SNY) RSV antibody, Beyfortus. J&J (JNJ) and Novartis (NVS) announce strong second-quarter results.
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $451.20, marking a +0.91% move from the previous day.
Lilly's (LLY) Donanemab Slows Alzheimer's Disease Progression
by Zacks Equity Research
Data from a phase III study shows that treatment with Eli Lilly's (LLY) donanemab slowed cognitive and functional decline by 60% in study participants at the earliest stage of Alzheimer's disease.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH